

## 学位論文抄録

Hyperglycaemia induces metabolic reprogramming into a glycolytic phenotype and promotes epithelial-mesenchymal transitions via YAP/TAZ-Hedgehog signalling axis in pancreatic cancer  
(高血糖は膵癌に代謝的リプログラミングを誘導し、YAP/TAZ-Hedgehog シグナル軸を介して上皮間葉系転移を促進する)

柳 昭

熊本大学大学院医学教育部博士課程医学専攻消化器外科学

指導教員

馬場 秀夫 教授

熊本大学大学院医学教育部博士課程医学専攻消化器外科学

## Abstract of the Thesis

**Background and Purpose:** Hyperglycemia is a well-known initial symptom in patients with pancreatic ductal adenocarcinoma (PDAC). Metabolic reprogramming in cancer, described as the Warburg effect, can induce epithelial-mesenchymal transition (EMT).

**Methods:** Biological impact of hyperglycemia on malignant behavior in PDAC was examined by *in vitro* and *in vivo* experiment. Clinical impact of hyperglycemia was investigated by immunohistochemical staining in patients with PDAC resection.

**Results:** Hyperglycemia promoted EMT by inducing metabolic reprogramming into a glycolytic phenotype via yes-associated protein (YAP)/PDZ-binding motif (TAZ) overexpression, accompanied by GLUT1 overexpression and enhanced phosphorylation Akt in PDAC. In addition, hyperglycemia enhanced chemoresistance by upregulating ABCB1 expression, and triggered PDAC switch into pure-basal-like subtype with activated Hedgehog pathway (GLI1 high, GATA6 low expression) through YAP/TAZ overexpression. PDAC is characterized by abundant stroma that harbors tumor-promoting properties and chemoresistance. Hyperglycemia promotes production of collagen fiber-related proteins (fibronectin, fibroblast activation protein, COL1A1, and COL11A1) by stimulating YAP/TAZ expression in cancer-associated fibroblasts (CAFs). Knockdown of YAP and/or TAZ or treatment with YAP/TAZ inhibitor (K975) abolished EMT, chemoresistance, and a favorable tumor microenvironment even under hyperglycemic conditions *in vitro* and *in vivo*.

**Conclusions:** Hyperglycemia induces metabolic reprogramming into glycolytic phenotype and promotes EMT via YAP/TAZ-Hedgehog signaling axis, and YAP/TAZ could be a novel therapeutic target in PDAC.